Results 31 to 40 of about 812,191 (301)
Strategies to enhance CAR-T persistence
Biomarker Research, 2022 Chimeric antigen receptor T (CAR-T) cell therapy has significantly improved the life expectancy for patients with refractory or relapse B cell lymphoma.
Yue Liu +6 more
doaj +1 more source
CAR-T Cell Therapy for Lymphoma [PDF]
Annual Review of Medicine, 2016 Lymphomas arise from clonal expansions of B, T, or NK cells at different stages of differentiation. Because they occur in the immunocyte-rich lymphoid tissues, they are easily accessible to antibodies and cell-based immunotherapy. Expressing chimeric antigen receptors (CARs) on T cells is a means of combining the antigen-binding site of a monoclonal ...
Carlos A, Ramos +2 more
openaire +2 more sources
healthbook TIMES. Oncology Hematology, 2019 During the entire 20^th^ century, chemotherapy and irradiation were the mainstay of non-surgical cancer treatment. In the past 20 years, however, cancer immunotherapy has been revolutionizing the field of oncology with ever-increasing pace.
Norman Russkamp, Thorsten Zenz
doaj +1 more source
Antigenic cells augment CAR T cells [PDF]
Blood, 2020 Publisher's Note: The Blood article that is discussed in this commentary has been retracted. The authors of this commentary were not involved with the original article's retraction.
openaire +2 more sources
Frontiers in Immunology, 2021 Chimeric antigen receptor (CAR) T cell performance against solid tumors in mouse models and clinical trials is often less effective than predicted by CAR construct selection in two-dimensional (2D) cocultures.
Laura Grunewald +34 more
doaj +1 more source
CAR-T cells targeting CD38 and LMP1 exhibit robust antitumour activity against NK/T cell lymphoma
BMC Medicine, 2023 Background Natural killer/T cell lymphoma (NKTCL) is an aggressive lymphoma with a poor prognosis. Chimeric antigen receptor-transduced T (CAR-T) cell therapy has become a promising immunotherapeutic strategy against haematologic malignancies. Methods In
Hongwen Li +10 more
doaj +1 more source
Treating MCL with CAR T Cells [PDF]
Cancer Discovery, 2020 Abstract KTE-X19, an investigational chimeric antigen receptor T-cell therapy, has shown promising efficacy in patients with relapsed/refractory mantle cell lymphoma. Based on data from the ZUMA-2 trial, it is now under the FDA's priority review and could soon be a new standard of care for this rare hematologic malignancy.
openaire +2 more sources
Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality
OncoImmunology, 2022 Successful translation of chimeric antigen receptor (CAR) T cell therapy for the treatment of solid tumors has proved to be troublesome, mainly due to the complex tumor microenvironment promoting T cell dysfunction and antigen heterogeneity.
Esther Schoutrop +8 more
doaj +1 more source
In Situ Programming of CAR T Cells [PDF]
Annual Review of Biomedical Engineering, 2021 Gene therapy makes it possible to engineer chimeric antigen receptors (CARs) to create T cells that target specific diseases. However, current approaches require elaborate and expensive protocols to manufacture engineered T cells ex vivo, putting this therapy beyond the reach of many patients who might benefit.
Parayath, Neha N., Stephan, Matthias T.
openaire +2 more sources
Mechanisms of CAR T cell exhaustion and current counteraction strategies
Frontiers in Cell and Developmental Biology, 2022 The functional state of chimeric antigen receptor T (CAR T) cells determines their efficacy in vivo. Exhausted CAR T cells exhibit decreased proliferative capacity, impaired anti-tumor activity, and attenuated persistence.
Xiaoying Zhu, Qing Li, Xiaojian Zhu
doaj +1 more source